Entera Bio Ltd. (NASDAQ:ENTX) Sees Large Increase in Short Interest

Entera Bio Ltd. (NASDAQ:ENTX) was the recipient of a large increase in short interest in October. As of October 31st, there was short interest totalling 44,200 shares, an increase of 9.4% from the October 15th total of 40,400 shares. Based on an average trading volume of 31,500 shares, the short-interest ratio is currently 1.4 days.

Hedge Funds Weigh In On Entera Bio

A number of hedge funds have recently modified their holdings of the stock. Virtu Financial LLC bought a new stake in Entera Bio in the first quarter valued at $37,000. Signature Estate & Investment Advisors LLC bought a new stake in shares of Entera Bio in the 3rd quarter worth about $90,000. Finally, Parkman Healthcare Partners LLC grew its holdings in shares of Entera Bio by 2.4% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 411,076 shares of the company’s stock worth $781,000 after purchasing an additional 9,558 shares during the last quarter. 14.11% of the stock is owned by institutional investors and hedge funds.

Entera Bio Stock Performance

NASDAQ:ENTX traded down $0.05 during mid-day trading on Friday, hitting $1.73. The company’s stock had a trading volume of 17,923 shares, compared to its average volume of 128,627. Entera Bio has a fifty-two week low of $0.52 and a fifty-two week high of $3.35. The stock has a fifty day moving average of $1.85 and a 200-day moving average of $1.91.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Entera Bio in a research report on Monday, November 11th.

Entera Bio Company Profile

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.